Instrument NameIteos Therapeutics IncInstrument Symbol(ITOS-Q)

Instrument ExchangeNASDAQ

/PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of...

/PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against...

USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently...

- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody,...

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it is strengthening its scientific team...

Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with...

Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients...

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab-gxly) and EOS-448 combination trial...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of...

MPM Capital (MPM), one of the world’s prominent biotech investment firms, has announced the addition of Detlev Biniszkiewicz, Ph.D. to its venture investment team as a Managing Director and Investment Committee member.

- First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 12, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated...

GOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody...